123724-56-1

Upstream product

• 123724-54-9 di-tert-butyl 4-benzoyl-L-glutamate 
• 124-63-0 methanesulfonyl chloride 
• 122-04-3 4-nitro-benzoyl chloride 
• 16874-06-9 Glutamic acid di-tert-butyl ester 
• 88050-23-1 Di-tert-butyl 4-nitrobenzoyl-L-glutamate 
• 130633-36-2 Di-tert-butyl 4-<(2-chloroethyl)amino>benzoyl-L-glutamate 
• 76282-66-1 Di-tert-butyl 4-aminobenzoyl-L-glutamate 
• 130633-37-3 Di-tert-butyl 4-<(2-chloroethyl)(2-hydroxyethyl)amino>benzoyl-L-glutamate 
• 32677-01-3 L-glutamic acid di-tert-butyl ester hydrochloride 
• 88050-23-1 di-tert-butyl (S)-N-(p-nitrobenzoyl)-glutamate 
• 76282-66-1 di-tert-butyl (S)-N-(p-aminobenzoyl)-glutamate 

Downstream Products

• 122665-70-7 4-[(2-chloroethyl)-(2-mesyloxyethyl)amino]benzoic acid 
• 122665-73-0 4-<(2-Chloroethyl)(2-mesyloxyethyl)amino>benzoyl-L-glutamic acid 
• 122665-73-0 CMDA 

Relevant academic research and scientific papers

SYNTHESIS OF AN N-MUSTARD PRODRUG

We describe the synthesis of the novel N-mustard prodrug 4-benzoyl-L-glutamic acid, which is designed for activation by tumour localising antibody-carboxypeptidase conjugates.

Novel Prodrugs Which Are Activated to Cytotoxic Alkylating Agents by Carboxypeptidase G2

The synthesis of three novel prodrugs, 4-amino>benzoyl-L-glutamic acid (7), 4-amino>benzoyl-L-glutamic acid (8), and 4-benzoyl-L-glutamic acid (9), for use as anticancer ag